GH Research PLC reported second quarter 2026 financial results on August 6, 2026. The company incurred a net loss of $15.1 million, or $0.23 per share, compared to a $9.3 million loss in the prior year period. For the six months ended June 30, 2026, total R&D expenses rose to $24.8 million from $16.8 million, driven by increased clinical development costs for its mebufotenin therapies. The company holds $362.7 million in cash and marketable securities as of June 30, 2026, following an underwritten equity offering in April that generated $111.2 million in net proceeds. Operationally, GH Research completed Phase 1 trials for its proprietary aerosol delivery device (GH001-HV-106) and its IND-opening trial in the US (GH001-HV-109). In July 2026, the FDA confirmed that CMC and device plans appear Phase 3 ready, with the company targeting pivotal program initiation later this year. Additionally, the U.S. Patent and Trademark Office granted a new patent for mebufotenin aerosol methods expiring no earlier than 2043, and the European Patent Office maintained key opposition claims. GH Research PLC is a clinical-stage biopharmaceutical company developing mebufotenin therapies for treatment-resistant depression.

GH Research PLC held its annual general meeting on June 25, 2026, where shareholders approved all board-recommended resolutions. These included the re-election of directors Florian Schönharting, Michael Forer, Dermot Hanley, and Duncan Moore, as well as the ratification of PricewaterhouseCoopers Ireland as independent auditors for the fiscal year ending December 31, 2026. The company operates in the biotechnology and drug discovery industry.